199 related articles for article (PubMed ID: 38672643)
1. NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors-A Retrospective Molecular Tumor Board Analysis.
Gremke N; Rodepeter FR; Teply-Szymanski J; Griewing S; Boekhoff J; Stroh A; Tarawneh TS; Riera-Knorrenschild J; Balser C; Hattesohl A; Middeke M; Ross P; Litmeyer AS; Romey M; Stiewe T; Wündisch T; Neubauer A; Denkert C; Wagner U; Mack EKM
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672643
[No Abstract] [Full Text] [Related]
2. NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU.
Sultova E; Westphalen CB; Jung A; Kumbrink J; Kirchner T; Mayr D; Rudelius M; Ormanns S; Heinemann V; Metzeler KH; Greif PA; Burges A; Trillsch F; Mahner S; Harbeck N; Wuerstlein R
Arch Gynecol Obstet; 2021 May; 303(5):1331-1345. PubMed ID: 33277683
[TBL] [Abstract][Full Text] [Related]
3. Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting.
Sultova E; Westphalen CB; Jung A; Kumbrink J; Kirchner T; Mayr D; Rudelius M; Ormanns S; Heinemann V; Metzeler KH; Greif PA; Hester A; Mahner S; Harbeck N; Wuerstlein R
Diagnostics (Basel); 2021 Apr; 11(4):. PubMed ID: 33924134
[TBL] [Abstract][Full Text] [Related]
4. Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients.
Canino F; Tornincasa A; Bettelli S; Manfredini S; Barbolini M; Moscetti L; Omarini C; Toss A; Tamburrano F; Antonelli G; Baglio F; Belluzzi L; Martinelli G; Natalizio S; Ponzoni O; Dominici M; Piacentini F
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473737
[TBL] [Abstract][Full Text] [Related]
5. Implementing precision oncology for sarcoma patients: the CCC
Berclaz LM; Burkhard-Meier A; Lange P; Di Gioia D; Schmidt M; Knösel T; Klauschen F; von Bergwelt-Baildon M; Heinemann V; Greif PA; Westphalen CB; Heinrich K; Lindner LH
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13973-13983. PubMed ID: 37542550
[TBL] [Abstract][Full Text] [Related]
6. Molecular Profile and Matched Targeted Therapy for Advanced Breast Cancer Patients.
Falcone R; Lombardi P; Filetti M; Fabi A; Altamura V; Scambia G; Daniele G
Curr Oncol; 2023 Feb; 30(2):2501-2509. PubMed ID: 36826152
[TBL] [Abstract][Full Text] [Related]
7. Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board.
Tarawneh TS; Rodepeter FR; Teply-Szymanski J; Ross P; Koch V; Thölken C; Schäfer JA; Gremke N; Mack HID; Gold J; Riera-Knorrenschild J; Wilhelm C; Rinke A; Middeke M; Klemmer A; Romey M; Hattesohl A; Jesinghaus M; Görg C; Figiel J; Chung HR; Wündisch T; Neubauer A; Denkert C; Mack EKM
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139590
[TBL] [Abstract][Full Text] [Related]
8. Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unit.
Walsh RJ; Ong R; Cheo SW; Low PQJ; Jayagopal A; Lee M; Ngoi N; Ow SG; Wong ALA; Lim SE; Lim YW; Heong V; Sundar R; Soo RA; Chee CE; Yong WP; Goh BC; Lee SC; Tan DSP; Lim JSJ
Front Oncol; 2024; 14():1342346. PubMed ID: 38812774
[TBL] [Abstract][Full Text] [Related]
9. Clinical Application of Next-Generation Sequencing in Patients With Breast Cancer: Real-World Data.
Suh KJ; Kim SH; Kim YJ; Shin H; Kang E; Kim EK; Lee S; Woo JW; Na HY; Ahn S; Jang BS; Kim IA; Park SY; Kim JH
J Breast Cancer; 2022 Oct; 25(5):366-378. PubMed ID: 35914747
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting.
VanderWalde A; Grothey A; Vaena D; Vidal G; ElNaggar A; Bufalino G; Schwartzberg L
J Pers Med; 2020 Nov; 10(4):. PubMed ID: 33260805
[TBL] [Abstract][Full Text] [Related]
11. The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours.
El Helali A; Lam TC; Ko EY; Shih DJH; Chan CK; Wong CHL; Wong JWH; Cheung LWT; Lau JKS; Liu APY; Chan ASY; Loong HH; Lam STS; Chan GC; Lee VHF; Yuen KK; Ng WT; Lee AWM; Ma ESK
Lancet Reg Health West Pac; 2023 Jul; 36():100775. PubMed ID: 37547050
[TBL] [Abstract][Full Text] [Related]
12. Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience.
Repetto M; Crimini E; Boscolo Bielo L; Guerini-Rocco E; Ascione L; Bonfanti A; Zanzottera C; Mazzarella L; Ranghiero A; Belli C; Criscitiello C; Esposito A; Barberis MCP; Curigliano G
Eur J Cancer; 2023 Apr; 183():79-89. PubMed ID: 36801623
[TBL] [Abstract][Full Text] [Related]
13. Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer Center.
Jain NM; Schmalz L; Cann C; Holland A; Osterman T; Lang K; Wiesner GL; Pal T; Lovly C; Stricker T; Micheel C; Balko JM; Johnson DB; Park BH; Iams W
Oncologist; 2021 Nov; 26(11):e1962-e1970. PubMed ID: 34390291
[TBL] [Abstract][Full Text] [Related]
14. Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice.
Bruzas S; Kuemmel S; Harrach H; Breit E; Ataseven B; Traut A; Rüland A; Kostara A; Chiari O; Dittmer-Grabowski C; Reinisch M
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572791
[TBL] [Abstract][Full Text] [Related]
15. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
Giacomini P; Valenti F; Allegretti M; Pallocca M; De Nicola F; Ciuffreda L; Fanciulli M; Scalera S; Buglioni S; Melucci E; Casini B; Carosi M; Pescarmona E; Giordani E; Sperati F; Jannitti N; Betti M; Maugeri-Saccà M; Cecere FL; Villani V; Pace A; Appetecchia M; Vici P; Savarese A; Krasniqi E; Ferraresi V; Russillo M; Fabi A; Landi L; Minuti G; Cappuzzo F; Zeuli M; Ciliberto G
J Transl Med; 2023 Oct; 21(1):725. PubMed ID: 37845764
[TBL] [Abstract][Full Text] [Related]
16. Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine.
Charo LM; Eskander RN; Sicklick J; Kim KH; Lim HJ; Okamura R; Lee S; Subramanian R; Schwab R; Shatsky R; Plaxe S; Kato S; Kurzrock R
JCO Precis Oncol; 2022 Jan; 6():e2000508. PubMed ID: 35005995
[TBL] [Abstract][Full Text] [Related]
17. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
18. Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer.
Rolfo C; Manca P; Salgado R; Van Dam P; Dendooven A; Ferri Gandia J; Rutten A; Lybaert W; Vermeij J; Gevaert T; Weyn C; Lefebure A; Metsu S; Van Laere S; Peeters M; Pauwels P; Machado Coelho A
ESMO Open; 2018; 3(5):e000398. PubMed ID: 30094075
[TBL] [Abstract][Full Text] [Related]
19. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
[TBL] [Abstract][Full Text] [Related]
20. Implementation and utilization of the molecular tumor board to guide precision medicine.
Harada S; Arend R; Dai Q; Levesque JA; Winokur TS; Guo R; Heslin MJ; Nabell L; Nabors LB; Limdi NA; Roth KA; Partridge EE; Siegal GP; Yang ES
Oncotarget; 2017 Aug; 8(34):57845-57854. PubMed ID: 28915716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
